揚帆新材(300637.SZ):29000t/a光引發劑、醫藥中間體項目的其它產品處於建設收尾和調試階段
格隆匯5月7日丨揚帆新材(300637.SZ)公佈,截止目前,29,000t/a光引發劑、醫藥中間體項目(一期工程中的3,000t/a光引發劑184和15,000t/a配套中間體產品)已完成工程主體建設及設備安裝、調試工作,試生產方案經專家組核查通過,認為該方案具備安全生產條件,項目將於近日組織進入試生產。
29,000t/a光引發劑、醫藥中間體項目的其它產品處於建設收尾和調試階段,公司將繼續採用邊建設邊投產的方案,分批對相關項目進行試產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.